WO2022225477A1 - Nano-fiber wound dressing - Google Patents
Nano-fiber wound dressing Download PDFInfo
- Publication number
- WO2022225477A1 WO2022225477A1 PCT/TR2021/051048 TR2021051048W WO2022225477A1 WO 2022225477 A1 WO2022225477 A1 WO 2022225477A1 TR 2021051048 W TR2021051048 W TR 2021051048W WO 2022225477 A1 WO2022225477 A1 WO 2022225477A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wound dressing
- solution
- dressing according
- production method
- subject
- Prior art date
Links
- 239000002121 nanofiber Substances 0.000 title claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 229920001661 Chitosan Polymers 0.000 claims description 13
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 13
- 229920005615 natural polymer Polymers 0.000 claims description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 13
- 229920001059 synthetic polymer Polymers 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 238000001523 electrospinning Methods 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 11
- 108010035532 Collagen Proteins 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 11
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 10
- 239000011118 polyvinyl acetate Substances 0.000 claims description 10
- 229920002413 Polyhexanide Polymers 0.000 claims description 9
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 7
- 229920001993 poloxamer 188 Polymers 0.000 claims description 7
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229940044519 poloxamer 188 Drugs 0.000 claims description 6
- 229940093158 polyhexanide Drugs 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 5
- 239000004632 polycaprolactone Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 241000239290 Araneae Species 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- -1 polyhexanite Polymers 0.000 claims 5
- 229920000728 polyester Polymers 0.000 claims 4
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 102000011632 Caseins Human genes 0.000 claims 2
- 108010076119 Caseins Proteins 0.000 claims 2
- 229920002101 Chitin Polymers 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 244000043261 Hevea brasiliensis Species 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 239000004952 Polyamide Substances 0.000 claims 2
- 229920002732 Polyanhydride Polymers 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 229920001800 Shellac Polymers 0.000 claims 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000005018 casein Substances 0.000 claims 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 2
- 235000021240 caseins Nutrition 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 229920005610 lignin Polymers 0.000 claims 2
- 229920003052 natural elastomer Polymers 0.000 claims 2
- 229920001194 natural rubber Polymers 0.000 claims 2
- 229920002647 polyamide Polymers 0.000 claims 2
- 239000004633 polyglycolic acid Substances 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940113147 shellac Drugs 0.000 claims 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 2
- 235000013874 shellac Nutrition 0.000 claims 2
- 239000004208 shellac Substances 0.000 claims 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 1
- 108010014258 Elastin Proteins 0.000 claims 1
- 108010022355 Fibroins Proteins 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229920002549 elastin Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 58
- 208000027418 Wounds and injury Diseases 0.000 abstract description 54
- 238000011282 treatment Methods 0.000 abstract description 6
- 239000007787 solid Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 71
- 239000002994 raw material Substances 0.000 description 15
- 230000029663 wound healing Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 208000012313 wound discharge Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Definitions
- the invention refers to a nanofiber solid, flexible and permeable wound dressing formed for cosmetic purposes or for the treatment of open wounds.
- Hydrocoil another wound dressing used in the technique, is a self-adhesive absorbent hydrocolloid wound dressing with a semi-permeable covering layer that is impermeable to microorganisms and water. Hydrocolloids turn into gel when they come into contact with wound discharge. They create a moist environment that provides a triggering effect on granulation and epithelization. This type of dressing, on the other hand, does not have an effect to remove the wound discharge from the environment since it is semi-permeable.
- Foam wound care products generally use polyurethane, which absorbs exudate, as a raw material and does not contain a wound healing component. In this case, there should be no infection on the wound to use the mentioned wound dressing. Moreover, because the fully permeable structure is not provided, the wound discharge cannot be removed from the environment.
- biocompatible PVA-gelatin core-shell composite nanofiber tissue scaffold consisting of Polyvinyl Alcohol (PVA or P) and bovine gelatin (GE) to be used as a supportive material in wound and burn treatments is produced using the electrospinning method with environmentally sound green production approach.
- the tissue must be completely free of bacteria to use the subject product. It is not suitable for bacteria-contaminated or infected wounds. Apart from this, it does not have any controlled molecule release feature.
- the wound dressings which contain polylactic acid (PLA), a polymer such as polycaprolactone (PCL) and chitosan are obtained by electrospinning method. While PCL is used with the core-shell structure in the application number TR201517118, PLA is used in the patent application number TR201617649.
- PLA polycaprolactone
- the present invention refers to a wound dressing that meets the aforementioned requirements, eliminates all disadvantages and brings some additional advantages.
- the primary purpose of the invention is to obtain a biocompatible wound dressing with self melting property of the dressing on the wound. Thanks to the formation of a wound dressing from the molecules that are good for the wound, the wound dressing disappears in the wound and it is not required to remove it from the wound. This provides an easy-to-use feature. Moreover, because it is not required to remove the wound dressing, which is the subject of this invention, from the wound, adhesion to the other wound and deformation, which is caused by that, on the skin can be prevented.
- Another purpose of the invention is to provide wound dressing with a controlled releasing.
- the spontaneous disappearance time of the wound dressing which is the subject of the invention, can be adjusted and it will make contributions to the rapid healing of the wound because it will release antimicrobial components into the wound environment in a controlled manner.
- a purpose of the invention is to eliminate the need for wound cleaning before application, thanks to the antibacterial agents in its content such as PHMB and chitosan. While it quickly contributes to wound healing, it also prevents the biofilm formation. Prevention of the biofilm created by bacteria on the wound surface is very important for wound healing.
- Another purpose of the invention is to obtain a nanofiber textured fully permeable wound dressing thanks to the electrospinning method used in production. In this way, while it removes the fluid formed in the wound from the environment, it also accelerates the wound healing process thanks to its air permeability.
- nanofiber solid, flexible and permeable wound dressing formed for cosmetic purposes or for the treatment of open wounds is developed.
- Figure-1 shows the SEM image of the wound dressing, which is a preferred arrangement of the invention and prepared with A, B, C and D solutions.
- nanofiber wound dressing which is selected individually or as a combination from the group of polyvinyl alcohol, polyvinyl acetate and hydrolyzed collagen, chitosan, Poloxamer 188, polyhexanide for cosmetic or medical use.
- the most fundamental component of the invention is a solution containing polyvinyl alcohol (PVA), polyvinyl acetate (PCA) and water.
- This solution is called solution A throughout the invention for an easy understandability.
- Table 1 shows the raw materials in solution A and a preferred amount of these raw materials that can be used in solution.
- Solution A should be used to create a nanofiber wound dressing with the electrospinning device.
- PVA and PCA which are used in the solution, have a structure that can spin the desired molecule in the magnetic field of the electrospinning device and retain it back into the nanofiber structure.
- the ratio of PVA and PCA allows to decide how long the molecules that provides healing and are desired to be used will perform a controlled release.
- Table 1 Table showing the raw materials in the content of solution A
- solution A and one or more solutions selected from the solution group - solution B, solution C and solution D - which are explained in detail below are used.
- Solution B consists of natural or synthetic polymer and water.
- the purpose of using natural or synthetic polymers in the solution is to obtain nanofiber composites.
- Table 2 below shows the natural or synthetic polymers that can be used in solution.
- Hydrolyzed collagen is preferably used in the invention.
- the subject hydrolyzed collagen may preferably be type I, type II or type III.
- Type I and type III which are the most suitable options for tissue and subcutaneous, are preferably preferred in the invention.
- Hydrolyzed collagen is used to support the existing collagen structure in the hypodermis layer under the skin. It is referred to as solution B for an easy understanding throughout the invention.
- Table 3 shows the raw materials in solution B and a preferred amount of these raw materials that can be used in solution.
- Solution C is a solution consisting of a natural or synthetic polymer, a solvent that dissolves the said polymer and water.
- Said natural or synthetic polymer can be selected from those mentioned in Table 2.
- chitosan Poly-D-Glucosamine
- acetic acid solution is preferred as a solvent for solution C.
- Chitosan can be dissolved in acetic acid. If another polymer is used, it is necessary to use another solvent. Chitosan is preferred because it prevents the formation of bacteria on the surfaces where it has contact, helps to eliminate harmful bacteria and has antibacterial properties. It is important to use chitosan within the specified range as it can affect the nanofiber structure. It is referred to as solution C for an easy understanding throughout the invention. Table 4 shows the raw materials in solution C and a preferred amount of these raw materials that can be used in solution.
- Table 4 Table showing the raw materials in the content of solution C
- Solution D is a solution consisting of a wound care molecule and water.
- poloxamer 188 Kerphor P 188
- polyhexanide Polyhexamethylene Biguanide PHMB
- Solution D for an easy understanding throughout the invention.
- Table 5 shows the raw materials in solution D and a preferred amount of these raw materials that can be used in solution.
- the solution A and, in addition to solution A, one or more solution which is selected among solution B, solution C and solution D can be combined to obtain a wound dressing.
- 50-99% Solution A can be used.
- the mentioned solution C is used at a maximum rate of 15% in the mixture.
- Another preferred arrangement of the invention is obtained by applying electro spinning method to 80% Solution A, 5% Solution B, 5% Solution C and 10% Solution D.
- Figure-1 shows the SEM image of the wound dressing, which is a preferred arrangement of the invention and prepared with solutions A, B, C and D via electrospinning.
- the obtained wound dressing has a spider web structure as it can be seen in Figure-1 and the nanofiber structure can be seen in the SEM image.
- Obtaining solution A Polyvinyl alcohol and Polyvinyl acetate are mixed with cold deionized water for 60 minutes in the proportions specified in Table 1 . Subsequently, the temperature is increased to a range between 50-95°C, preferably to 85°C, and the mixture is mixed until it becomes homogeneous in the mixer heater. The temperature of Polyvinyl alcohol mixture is an important parameter. Polyvinyl alcohol and polyvinyl acetate can be used in the range of 1-20% depending on the controlled release time of the desired wound care material.
- Obtaining solution B Hydrolyzed collagen is dissolved in deionized water within the proportions specified in Table 3. It is mixed in a magnetic stirrer to be dissolved homogeneously.
- Obtaining solution C Acetic acid is dissolved in deionized water within the proportions specified in Table 4. Chitosan is added to the solution in a sealed container and mixed in a mixer. The mixed solution C is then mixed in an ultrasonic bath to accelerate the dissolution and make the solution homogeneous.
- a wound dressing solution which absolutely consists of solution A in a usable proportion, is prepared preferably with solution B, solution C and solution D.
- the said composition is mixed for at least 1 hour to obtain a homogeneous structure. Then, it is mixed for about half an hour in an ultrasonic bath at a temperature which do not exceed 25°C.
- the wound dressing solution which is taken into an injector, obtains its wound dressing form thanks to the electrospinning method via electrospinning device at a feeding speed of 1 ,5 ml/hour.
- the solution which is formed at a certain speed, reaches adequately suitable magnetic field, it enters into the electronic spinning and glides through the magnetic field and splashes to the non-flammable/non-stick paper to form a nanofiber structure.
- This application can be performed from 1 hour to 144 hours depending on the thickness of the wound care material. Voltage is 40kv.
- the above mentioned process should be carried out at a temperature between 12-25°C.
- the pH range that can be used for the wound dressing solution is 4.5-7, and the preferred pH range is 5-7. While the process is being carried out, the environment has 70% humidity.
- the product can be sterilized optionally with the help of gamma or similar rays especially after it is produced.
- the wound dressing obtained with solution A, B, C and D is indicated for the treatment of open wounds, burns or diabetic patients undergoing chronic wound treatment. This feature of the wound dressing puts itself to the class III, medical device class.
- a cosmetic-class care mask can be obtained that is suitable for the face and skin.
- a cosmetic-class face care mask is obtained by combining the solution A with the hyaluronate solution,
- the product can be used as a surgical thread which is a wound covering and suture material.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention refers to a nano-fiber solid, flexible and permeable wound dressing formed for cosmetic purposes or for the treatment of open wounds.
Description
A Nano-Fiber Wound Dressing
Technical Field
The invention refers to a nanofiber solid, flexible and permeable wound dressing formed for cosmetic purposes or for the treatment of open wounds.
Known Version of the Technique
When the current practices are analyzed, it is known that there is a wide variety of wound care products. These are spongy products which are made from various raw materials. Some of them are produced using textile technology. Others use polyurethane as a raw material.
Hydrocoil, another wound dressing used in the technique, is a self-adhesive absorbent hydrocolloid wound dressing with a semi-permeable covering layer that is impermeable to microorganisms and water. Hydrocolloids turn into gel when they come into contact with wound discharge. They create a moist environment that provides a triggering effect on granulation and epithelization. This type of dressing, on the other hand, does not have an effect to remove the wound discharge from the environment since it is semi-permeable.
Another type of wound dressing used recently is in foam form. Foam wound care products generally use polyurethane, which absorbs exudate, as a raw material and does not contain a wound healing component. In this case, there should be no infection on the wound to use the mentioned wound dressing. Moreover, because the fully permeable structure is not provided, the wound discharge cannot be removed from the environment.
One of the patents about this subject in the literature is the application number TR201904572. Within the scope of this invention, biocompatible PVA-gelatin core-shell composite nanofiber tissue scaffold consisting of Polyvinyl Alcohol (PVA or P) and bovine gelatin (GE) to be used as a supportive material in wound and burn treatments is produced using the electrospinning method with environmentally sound green production approach. The tissue must be completely free of bacteria to use the subject product. It is not suitable for
bacteria-contaminated or infected wounds. Apart from this, it does not have any controlled molecule release feature.
In patent application numbers TR201517118 and TR201617649, the wound dressings which contain polylactic acid (PLA), a polymer such as polycaprolactone (PCL) and chitosan are obtained by electrospinning method. While PCL is used with the core-shell structure in the application number TR201517118, PLA is used in the patent application number TR201617649.
As a result, it is required to make an improvement in the relevant technical field due to the above-mentioned negativities and the insufficiency of present solutions.
Purpose of the Invention
The present invention refers to a wound dressing that meets the aforementioned requirements, eliminates all disadvantages and brings some additional advantages.
The primary purpose of the invention is to obtain a biocompatible wound dressing with self melting property of the dressing on the wound. Thanks to the formation of a wound dressing from the molecules that are good for the wound, the wound dressing disappears in the wound and it is not required to remove it from the wound. This provides an easy-to-use feature. Moreover, because it is not required to remove the wound dressing, which is the subject of this invention, from the wound, adhesion to the other wound and deformation, which is caused by that, on the skin can be prevented.
Another purpose of the invention is to provide wound dressing with a controlled releasing. In this way, the spontaneous disappearance time of the wound dressing, which is the subject of the invention, can be adjusted and it will make contributions to the rapid healing of the wound because it will release antimicrobial components into the wound environment in a controlled manner.
Wound dressings used in the current technique and applied without cleaning have a negative effect on wound healing. A purpose of the invention is to eliminate the need for wound cleaning before application, thanks to the antibacterial agents in its content such as PHMB and chitosan. While it quickly contributes to wound healing, it also prevents the biofilm formation. Prevention of the biofilm created by bacteria on the wound surface is very important for wound healing.
Another purpose of the invention is to obtain a nanofiber textured fully permeable wound dressing thanks to the electrospinning method used in production. In this way, while it removes the fluid formed in the wound from the environment, it also accelerates the wound healing process thanks to its air permeability.
In order to fulfill the abovementioned objectives, a nanofiber solid, flexible and permeable wound dressing formed for cosmetic purposes or for the treatment of open wounds is developed.
Explanation of Figures
Figure-1 shows the SEM image of the wound dressing, which is a preferred arrangement of the invention and prepared with A, B, C and D solutions.
Detailed Explanation of the Invention
In this detailed explanation, the preferred arrangements of wound dressing, which is the subject of the invention, are explained only for a better understanding of the subject and without any restrictive effect.
In its most basic form, it is a nanofiber wound dressing which is selected individually or as a combination from the group of polyvinyl alcohol, polyvinyl acetate and hydrolyzed collagen, chitosan, Poloxamer 188, polyhexanide for cosmetic or medical use.
The most fundamental component of the invention is a solution containing polyvinyl alcohol (PVA), polyvinyl acetate (PCA) and water. This solution is called solution A throughout the invention for an easy understandability. Table 1 shows the raw materials in solution A and a preferred amount of these raw materials that can be used in solution. Solution A should be used to create a nanofiber wound dressing with the electrospinning device. PVA and PCA, which are used in the solution, have a structure that can spin the desired molecule in the magnetic field of the electrospinning device and retain it back into the nanofiber structure. The ratio of PVA and PCA allows to decide how long the molecules that provides healing and are desired to be used will perform a controlled release.
Table 1. Table showing the raw materials in the content of solution A
While the invention obtains the most fundamental form of wound dressing, solution A and one or more solutions selected from the solution group - solution B, solution C and solution D - which are explained in detail below are used.
Solution B consists of natural or synthetic polymer and water. The purpose of using natural or synthetic polymers in the solution is to obtain nanofiber composites. Table 2 below shows the natural or synthetic polymers that can be used in solution.
Table 2. Table showing natural and synthetic polymers
Hydrolyzed collagen is preferably used in the invention. The subject hydrolyzed collagen may preferably be type I, type II or type III. Type I and type III, which are the most suitable options for tissue and subcutaneous, are preferably preferred in the invention. Hydrolyzed collagen is used to support the existing collagen structure in the hypodermis layer under the skin. It is referred to as solution B for an easy understanding throughout the invention. Table 3 shows the raw materials in solution B and a preferred amount of these raw materials that can be used in solution.
Table 3. Table showing the raw materials in the content of solution B
Solution C is a solution consisting of a natural or synthetic polymer, a solvent that dissolves the said polymer and water. Said natural or synthetic polymer can be selected from those mentioned in Table 2. In the invention, chitosan (Poly-D-Glucosamine) is preferred as a natural or synthetic polymer, and acetic acid solution is preferred as a solvent for solution C. Chitosan can be dissolved in acetic acid. If another polymer is used, it is necessary to use another solvent. Chitosan is preferred because it prevents the formation of bacteria on the surfaces where it has contact, helps to eliminate harmful bacteria and has antibacterial properties. It is important to use chitosan within the specified range as it can affect the nanofiber structure. It is referred to as solution C for an easy understanding throughout the invention. Table 4 shows the raw materials in solution C and a preferred amount of these raw materials that can be used in solution.
Table 4. Table showing the raw materials in the content of solution C
Solution D is a solution consisting of a wound care molecule and water. In the invention, preferably poloxamer 188 (Kolliphor P 188), polyhexanide (Polyhexamethylene Biguanide PHMB) are used. Polyhexanide is used for its contribution to wound healing. It is referred to as solution D for an easy understanding throughout the invention. Table 5 shows the raw materials in solution D and a preferred amount of these raw materials that can be used in solution.
Table 5. Table showing the raw materials in the content of solution D
Within the scope of the invention, the solution A and, in addition to solution A, one or more solution which is selected among solution B, solution C and solution D can be combined to obtain a wound dressing. In a preferred arrangement of the invention, 50-99% Solution A can be used. In another preferred arrangement of the invention, the mentioned solution C is used at a maximum rate of 15% in the mixture. Another preferred arrangement of the invention is obtained by applying electro spinning method to 80% Solution A, 5% Solution B, 5% Solution C and 10% Solution D.
Figure-1 shows the SEM image of the wound dressing, which is a preferred arrangement of the invention and prepared with solutions A, B, C and D via electrospinning. The obtained wound dressing has a spider web structure as it can be seen in Figure-1 and the nanofiber structure can be seen in the SEM image.
The production of the wound dressing, which is subject to the invention, is explained in detail below:
Obtaining solution A: Polyvinyl alcohol and Polyvinyl acetate are mixed with cold deionized water for 60 minutes in the proportions specified in Table 1 . Subsequently, the temperature is increased to a range between 50-95°C, preferably to 85°C, and the mixture is mixed until it becomes homogeneous in the mixer heater. The temperature of Polyvinyl alcohol mixture is an important parameter. Polyvinyl alcohol and polyvinyl acetate can be used in the range of 1-20% depending on the controlled release time of the desired wound care material.
Obtaining solution B: Hydrolyzed collagen is dissolved in deionized water within the proportions specified in Table 3. It is mixed in a magnetic stirrer to be dissolved homogeneously.
Obtaining solution C: Acetic acid is dissolved in deionized water within the proportions specified in Table 4. Chitosan is added to the solution in a sealed container and mixed in a mixer. The mixed solution C is then mixed in an ultrasonic bath to accelerate the dissolution and make the solution homogeneous.
Obtaining solution D: Poloxamer 188 and polyhexanide are mixed in deionized water within the proportions specified in Table 5 in a separate container.
After the aforementioned solutions are mixed, a wound dressing solution, which absolutely consists of solution A in a usable proportion, is prepared preferably with solution B, solution C and solution D. The said composition is mixed for at least 1 hour to obtain a homogeneous structure. Then, it is mixed for about half an hour in an ultrasonic bath at a temperature which do not exceed 25°C.
After the homogeneous structure is provided, the wound dressing solution, which is taken into an injector, obtains its wound dressing form thanks to the electrospinning method via electrospinning device at a feeding speed of 1 ,5 ml/hour. When the solution, which is formed at a certain speed, reaches adequately suitable magnetic field, it enters into the electronic spinning and glides through the magnetic field and splashes to the non-flammable/non-stick paper to form a nanofiber structure. This application can be performed from 1 hour to 144 hours depending on the thickness of the wound care material. Voltage is 40kv.
The above mentioned process should be carried out at a temperature between 12-25°C. The pH range that can be used for the wound dressing solution is 4.5-7, and the preferred pH range is 5-7. While the process is being carried out, the environment has 70% humidity. The product can be sterilized optionally with the help of gamma or similar rays especially after it is produced.
The wound dressing obtained with solution A, B, C and D is indicated for the treatment of open wounds, burns or diabetic patients undergoing chronic wound treatment. This feature of the wound dressing puts itself to the class III, medical device class.
When the solutions A and B are used together, a cosmetic-class care mask can be obtained that is suitable for the face and skin. In another preferred arrangement of the invention, a cosmetic-class face care mask is obtained by combining the solution A with the hyaluronate solution,
In addition to the solutions A and B, when the solutions C and D are used which have wound healing and disinfecting features, the product can be used as a surgical thread which is a wound covering and suture material.
Claims
1. It is a nanofiber wound dressing for cosmetic or medical use, and it is characterized in that it contains
- polyvinyl alcohol,
- polyvinyl acetate and
- substances selected individually or as a combination from the group of natural polymer, synthetic polymer, Poloxamer 188, polyhexanite, sodium hyaluronate solution.
2. It is a wound dressing according to Claim 1 , and it is characterized in that a natural or synthetic polymer is hydrolyzed collagen and/or chitosan.
3. It is a wound dressing according to Claim 2, and it is characterized in that the said hydrolyzed collagen is type I or type III.
4. It is a wound dressing according to Claim 1 , and it is characterized in that it is individually or as a combination among the groups of subject natural and synthetic polymers, starch, cellulose, chitin, polysaccharide as chitosan, collagen, casein, albumin, fibrinogen, silk, silk fibroin, protein as elastin, polyester as polyhydroxyalkanate, lignin, lipets, shellac, natural rubber, polyamide, polyanhydride, polyamide-enamine, polyglycolic acid, polylactic acid, polycaprolactone, polyester as polyorthoester, polyethylene oxide, polyurethane and polyphosphazen.
5. It is a wound dressing according to Claim 1 , and it is characterized in that it has a spider web structure.
6. It is a wound dressing for cosmetic or medical purposes, and it is characterized in that it has these steps in its process:
- Obtaining solution A by mixing polyvinyl alcohol and polyvinyl acetate with deionized water,
- mixing the subject solution A with one or more solutions selected from the group below, o Solution B which is obtained by mixing natural or synthetic polymer and deionized water,
o Solution C which is obtained by adding natural or synthetic polymer to the solution obtained after dissolving the solvent in deionized water o Solution D which is obtained by mixing Poloxamer 188 and polyhexanide in deionized water o sodium hyaluronate solution
- Transforming the mixture which is obtained in the previous process step into a wound dressing by electrospinning method
7. It is the production method of wound dressing according to Claim 6, and it is characterized in that it is individually or as a combination among the groups of subject natural and synthetic polymers, starch, cellulose, chitin, polysaccharide as collagen, casein, albumin, fibrinogen, protein as silk, polyester as polyhydroxyalkanate, lignin, lipets, shellac, natural rubber, chitosan, polyamide, polyanhydride, polyamide-enamine, Polyglycolic acid, Poliorlactic acid, Polycaprolactone, polyester as Polyorholactone, polyethylene oxide, and polyphosphatans.
8. It is the production method of wound dressing according to Claim 6, and it is characterized in that the ratio of the subject Solution A is 50-99% in the obtained solution.
9. It is the production method of wound dressing according to Claim 6, and it is characterized in that the ratio of the subject Solution C is maximum 15% in the obtained solution
10. It is the production method of wound dressing according to Claim 6, and it is characterized in that the mixture consists of 80% Solution A, 5% Solution B, 5% Solution C and 10% Solution D.
11. lt is the production method of wound dressing according to Claim 6, and it is characterized in that the subject solution A contains 1-20% polyvinyl alcohol, 1-20% polyvinyl acetate and 60-98% deionized water.
12. It is the production method of wound dressing according to Claim 6, and it is characterized in that the subject solution B contains 1 -30% hydrolyzed collagen and 70-99% deionized water.
13. It is the production method of wound dressing according to Claim 6, and it is characterized in that the subject Solution C contains 1-20% chitosan, 0.1-20% acetic acid and 60-98.9% deionized water.
14. It is the production method of wound dressing according to Claim 6, and it is characterized in that the subject solution D contains 1-20% Poloxamer 188, 0.1-20% polyhexanide and 60-98.9% deionized water.
15. lt is the production method of wound dressing according to Claim 6, and it is characterized in that the subject mixing action is performed for at least 1 hour in the process step of mixing the subject Solution A with one or more solutions selected from the group.
16. lt is the production method of wound dressing according to Claim 15, and it is characterized in that it is mixed in the ultrasonic bath for about half an hour after the said mixing process,
17. It is the production method of wound dressing according to Claim 6, and it is characterized in that it is obtained on non-flammable/non-stick paper during the process of obtaining a wound dressing with electrospinning method.
18. It is the production method of wound dressing according to Claim 6, and it is characterized in that the method is performed at between 12 °C and 25°C.
19. It is the production method of wound dressing according to Claim 6, and it is characterized in that its pH value is between 4.5 and 7.
20. It is the production method of wound dressing according to Claim 6, and it is characterized in that electrospinning process is done for 1 -144 hours depending on the thickness of the wound dressing which is required to be obtained.
21. Use of the wound dressing as a face/skin care mask in cosmetic class according to Claims 1-5.
22. Use of wound dressing as a wound dressing according to Claims 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21938076.3A EP4326351A1 (en) | 2021-04-22 | 2021-10-14 | Nano-fiber wound dressing |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR202106995 | 2021-04-22 | ||
| TR2021/006995 TR2021006995A1 (en) | 2021-04-22 | A Nanofiber Care Cover |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022225477A1 true WO2022225477A1 (en) | 2022-10-27 |
Family
ID=83723109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2021/051048 WO2022225477A1 (en) | 2021-04-22 | 2021-10-14 | Nano-fiber wound dressing |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4326351A1 (en) |
| WO (1) | WO2022225477A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100055153A1 (en) * | 2008-09-03 | 2010-03-04 | Transdermal Innovations Inc. | Multipurpose hydrogel compositions and products |
| WO2016123693A1 (en) * | 2015-02-06 | 2016-08-11 | The University Of British Columbia | Engineered tissue substitute system |
-
2021
- 2021-10-14 EP EP21938076.3A patent/EP4326351A1/en active Pending
- 2021-10-14 WO PCT/TR2021/051048 patent/WO2022225477A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100055153A1 (en) * | 2008-09-03 | 2010-03-04 | Transdermal Innovations Inc. | Multipurpose hydrogel compositions and products |
| WO2016123693A1 (en) * | 2015-02-06 | 2016-08-11 | The University Of British Columbia | Engineered tissue substitute system |
Non-Patent Citations (2)
| Title |
|---|
| JANNESARI ET AL.: "Composite poly(vinyl alcohol)/poly(vinyl acetate) electrospun nanofibrous mats as a novel wound dressing matrix for controlled release of drugs", INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 6, 2011, pages 993 - 1003, XP055524071, DOI: 10.2147/IJN.S17595 * |
| YUN OK KANG ET AL.: "Chitosan-Coated Poly(vinyl alcohol) Nanofibers For Wound Dressing", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B:APPLIED BIOMATERIALS, 2009 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4326351A1 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2468129C2 (en) | Biopolymeric fibre, composition of forming solution for its obtaining, method of forming solution preparation, linen of biomedical purpose, biological bandage and method of wound treatment | |
| RU2369408C2 (en) | Hemostatic composition comprising hyaluronic acid | |
| AU2002365662B2 (en) | Wound dressings | |
| CA2928336C (en) | Bioactive collagen biomaterials and methods for making | |
| US10293075B2 (en) | Ready-to-use, hydrophilic, self-dispersive, fragmentable and biodegradable porous sponge matrix and a method of manufacturing thereof | |
| WO1998057676A1 (en) | Wound covering material containing silk fibroin and silk sericin as the main components and process for producing the same | |
| CN107754005B (en) | Hemostatic compositions and methods of making same | |
| KR20070118730A (en) | Wound dressing materials with excellent ability to moisturized skin and method of manufacturing the same | |
| TW200925342A (en) | Method for production of nanofibres | |
| JP5394600B2 (en) | Absorbable medical synthetic coating material, its preparation and its medical use | |
| JP2017532178A (en) | Wound dressing tool | |
| CN107693835A (en) | A kind of polyvinyl alcohol/collagen/n-trimethyl chitosan chloride electrospun composite fibers film and preparation method thereof | |
| RU2596502C2 (en) | Biodegradable non-woven material for medical purposes | |
| RU135921U1 (en) | HEMOSTATIC MEDICAL PRODUCT | |
| JP2003525703A (en) | Novel natural polymer-based materials with improved properties for use in human and veterinary medicine and methods for their production | |
| Shahriari Khalaji et al. | Biomedical application of cotton and its derivatives | |
| Chellamani et al. | Chitosan treated textile substrates for wound care applications | |
| Wang et al. | A sequential therapeutic hydrogel with injectability and antibacterial activity for deep burn wounds’ cleaning and healing | |
| EP4326351A1 (en) | Nano-fiber wound dressing | |
| RU2240140C2 (en) | Medicinal multilayer bandage and articles based on such bandage | |
| US20120282320A1 (en) | Hemostatic dressing | |
| TR2021006995A1 (en) | A Nanofiber Care Cover | |
| CN108939136B (en) | Dressing for nasal filling hemostasis and preparation method thereof | |
| Tamilarasi et al. | Electrospun scaffold-based antibiotic therapeutics for chronic wound recovery | |
| Pamfil et al. | Collagen‐Based Materials for Pharmaceutical Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21938076 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2021938076 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2021938076 Country of ref document: EP Effective date: 20231122 |